investigator_user
investigator
user
funding
collaborators
pending
menu
bell
message
arrow_up
arrow_down
filter
layers
globe
marker
add
arrow
close
download
edit
facebook
info
linkedin
minus
plus
save
share
search
sort
twitter
remove
user-plus
user-minus
Sign Up for Updates
Map
Countries
Cancer types
All cancers but non-melanoma skin cancer
Bladder
Brain, nervous system
Breast
Cervix uteri
Colorectum
Corpus uteri
Gallbladder
Hodgkin lymphoma
Kaposi sarcoma
Kidney, renal pelvis and ureter
Larynx
Leukaemia
Lip, oral cavity
Liver and intrahepatic bile ducts
Melanoma of skin
Multiple myeloma and immunoproliferative diseases
Nasopharynx
Non-Hodgkin lymphoma
Non-Melanoma skin cancer
Oesophagus
Other pharynx
Ovary
Pancreas
Prostate
Sarcoma
Stomach
Testis
Thymus
Thyroid
Trachea, bronchus and lung
Specialities
Hematology and hematologic malignancies
Palliative Care
Pathology
Pediatric oncology or childhood cancer
Radiation Oncology
Surgery / Surgical oncology
Blog
About
Login
Project leads
Collaborators
Sex Hormone Receptor Components and the Cell Genome
Bert W O'Malley
0 Collaborator(s)
Funding source
National Institutes of Health (NIH)
Follow
+ Project
+ Post
+ Event
Info
People
Posts
Bert W O'Malley
Baylor College of Medicine
Houston, United States
Dan L. Duncan Cancer Center
Waco, United States
Related projects
Hans Schreiber
Immunology of Unique Tumor Specific Antigens
Breast
Donald W. Kufe
Oncogenic Signaling by DF3/MUC1 in Human Breast Cancer
Breast
Joe W Gray
Model-based Predictions of Responses RTK Pathway Therapies
Breast
Javed Khan
Targeting FGFR4, RAS, and PAX3-FOXO1 Gene in Rhabdomyosarcoma
Breast
Pediatric oncology or childhood cancer
Gregg B Fields
Mechanism and Inhibition of Collagenolytic Activity
Breast
Heide L Ford
Role of Six1 and the miR106b 25 Cluster in EMT and Tumor Progression
Breast
Sara Lindstroem
Quantifying and Characterizing the shared genetic contribution to common cancers
Breast
Carlo M Croce
MiRNAs/UCRs: Biomarkers for Cancer Risk, Tumor Detection, Progression and Treatment
Breast
Nathanael S Gray
Developing Selective EphA2 Inhibitors for the Treatment of Cancer
Breast
